Physician profile
Arup Maitra
NPI 1760473763
$2,309.19
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $120 · 2021: $258 · 2022: $682 · 2023: $580 · 2024: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941 · Education: $82.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.97 |
| Education | $82.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $378.49 | 2019-2024 | Farxiga |
| Amgen INC. | $255.21 | 2019-2024 | Tavneos |
| Fresenius USA Marketing, INC. | $233.94 | 2021-2024 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $162.85 | 2019-2024 | Jynarque |
| Vifor Pharma, INC. | $158.61 | 2019-2024 | Veltassa, Korsuva |
| Horizon Therapeutics Plc | $156.63 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.81 | 2022-2024 | |
| Calliditas Therapeutics US INC. | $143.06 | 2022-2024 | Tarpeyo |
| Travere Therapeutics, INC. | $132.43 | 2023-2024 | |
| Akebia Therapeutics INC | $127.66 | 2020-2023 | Auryxia |
| Novartis Pharmaceuticals Corporation | $79.78 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $77.91 | 2023-2024 | Lupkynis |
| Nxstage Medical, INC. | $53.06 | 2019 | |
| Opko Pharmaceuticals, LLC | $44.82 | 2023 | Rayaldee |
| La Jolla Pharmaceutical Company | $38.05 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $23.48 | 2024 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.53 | 2024 | Jardiance |
| Ardelyx, INC. | $17.20 | 2024 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.55 | 2021 | |
| Genzyme Corporation | $14.15 | 2019 | |
| Lilly USA, LLC | $14.13 | 2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arup Maitra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.